HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the “C.C. Tan Life Science Industrialization Award”. C.C. Tan Life Science Award has the highest honor as “the Chinese Nobel” in life science. In the context of the comprehensive construction of Chinese-style modernization and the development of new productivity, this award is a high recognition of Dr. Chen Li's outstanding contributions to the industrialization of life science achievements, and a full affirmation of his decades-long efforts to promote conceptual, technological and institutional innovations in biopharmaceutical industry.Dr. Chen Li participated in the award ceremony and received the “C.C. TanLife Science Industrialization Award”.“C.C. Tan Life Science Award” was proposed by Mr. Tan Jiazhen, one of the founders of modern genetics in China and an outstanding scientist and educator in modern China, which was approved by the Ministry of Science and Technology of the People's Republic of China, aims to promote the industrialization of China's life sciences research results and stimulate life scientists to make innovations. Since its establishment in 2008, C.C. Tan Life Science Award has been awarded annually to scientists, professors and young scholars who have made achievements in life science in the People's Republic of China and have made outstanding contributions to the industrialization of scientific and technological achievements in life science.With more than 30 years of experience in new drug R&D and management, Dr. Chen Li returned to Shanghai from the U.S. in 2004, and participated in the establishment of Roche R&D Center, the first R&D center of a multinational company in Shanghai, bringing the advanced experience, talent concept, technical standards and quality management system of international new drug R&D to China, and contributing to the establishment of the environment of China's biopharmaceutical industry. Dr. Chen Li has contributed to the establishment of China's biopharmaceutical industry environment.In 2010, Dr. Chen Li founded Hua Medicine in Zhangjiang, Shanghai, with the original intention of “China leads the way in pharmaceutical innovation”, adhering to the tenet of “patients first, innovation first, and good medicines for the people”, focusing on the unmet clinical needs, and concentrating on the research and development of first-of-its-kind new medicines for diabetes. Dr. Chen Li is not only one of the earliest pioneers to leave his executive position at a multinational pharmaceutical company to start a local innovative drug company, but also a leader in developing First-in-Class drugs in China.In September 2022, under the leadership of Dr. Chen Li, Hua Medicine's world's first, China's first, Class I National New Drug, Dorzagliatin (trade name: HuaTangNing®), which took ten years to develop independently, received marketing approval from the State Food and Drug Administration (SFDA), making it the first Glucose Kinesin Activator (GKA) approved and marketed globally, and the tenth class of diabetes therapeutic drugs.As the world's first GKA drug, Dorzagliatin utilizes the new concept of “repairing sensing, reshaping homeostasis, and treating diabetes at the source” to achieve the improvement of blood glucose homeostasis dysregulation in patients with type 2 diabetes mellitus, and to bring a brand-new treatment for diabetes mellitus patients, which is a major breakthrough in the history of drug research and development of China in the field of major chronic diseases. During the development of Hua Medicine, Dr. Chen Li has actively contributed to the development of China's biopharmaceutical industry. He has provided constructive opinions and suggestions for the system of marketing license holders and the system of patent linkage and patent protection, etc. He has cooperated with enterprises in the industry chain in the R&D and production of dorzagliatin to establish a joint innovation model, which has led to the development of the ecological development of the biopharmaceutical industry. In early 2024, Dr. Chen Li was awarded the first “Shanghai Outstanding Talent”. He is also the inventor of 119 granted invention patents and 270 invention patent applications and has been published more than 70 scientific papers in Nature Medicine, Lancet Diabetes Endocrinology, Nature Communication, PNAS, Diabetes, Obesity Metabolism, and the Journal of Biomedicine. PNAS, Diabetes, Obesity Metabolism, JACS, JOC and other international academic journals.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

DUBAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Dubai International Financial Centre (DIFC), the leading global financial hub in the Middle East, Africa and South Asia (MEASA) region, announces the 2nd edition of the Future Sustainability Forum. Scheduled for 4 and 5 December 2024 at the Madinat Jumeirah, Dubai, the Forum will focus on mobilising sustainable practices, engaging in influential discussions on sustainable development, working towards environmental conservation, social equity and innovation.The announcement of the 2nd edition of the Forum underscores DIFC’s commitment to advancing UAE sustainability priorities alongside initiatives such as the DIFC Sustainable Finance Catalyst which aims to grow sustainable finance flows from Dubai to USD 100+ billion by 2030.The Forum coincides with the first anniversary of COP28 being hosted in the UAE and is set to attract over 3,000 participants. The event will mobilise industry leaders, investors, tech disruptors, and policymakers into achieving the United Nations Sustainable Development Goals (SDGs) and contributing to the delivery of the Paris Agreement, whilst aiming to channel investment flows between the global north and south to accelerate climate action.Alya Al Zarouni, Chief Operating Officer of DIFC Authority and Co-Chair of the Dubai Sustainable Finance Working Group, said, “The DIFC organised Future Sustainability Forum is a vital platform for collaborative action towards a more sustainable future. As the global economic landscape evolves, so must our commitment to responsible and inclusive growth. At DIFC, we are proud to be convening this gathering of industry leaders, innovators, and policymakers to address the most pressing environmental and social challenges of our time. Together, we can forge new pathways to a more resilient and sustainable future for financial services and other important industries.”Dr Bernd van Linder, Chief Executive Officer of the Commercial Bank of Dubai, the presenting sponsor of the Forum, stated, "Commercial Bank of Dubai is proud to support the UAE's sustainability ambitions through our participation in the Future Sustainability Forum 2024 as Presenting Sponsor. Our proactive approach in addressing environmental challenges, exemplified by the successful issuance of CBD's inaugural green bond, demonstrates our alignment with global environmental goals."The Forum will address critical sustainability issues across eight core pillars spanning different industries including banking and finance, construction, renewable and future energy, transportation and mobility, manufacturing and production, recycling and waste management, sustainable technology, and agriculture and food production.In addition to the packed conference agenda that will feature over 100 sustainability and climate action expert speakers, the Forum will bring together the most innovative solutions and service providers from across the global sustainability landscape through the Climate Action & Renewable Energy Expo (CARE).Government entities in the UAE have spearheaded a range of comprehensive sustainability programmes in the pursuit of a net-zero future. Initiatives such as the Dubai Clean Energy Strategy 2050, the UAE Net Zero 2050 strategic initiative, and the UAE Vision 2070, emphasise on a commitment to renewable energy adoption, water conservation, waste management, and sustainable urban development.For more information and to register, please visit the Future Sustainability Forum website.About Dubai International Financial CentreDubai International Financial Centre (DIFC) is one of the world’s most advanced financial centres, and the leading financial hub for the Middle East, Africa, and South Asia (MEASA), which comprises 77 countries with an approximate population of 3.7bn and an estimated GDP of USD 10.5trn.With a 20-year track record of facilitating trade and investment flows across the MEASA region, the Centre connects these fast-growing markets with the economies of Asia, Europe, and the Americas through Dubai. DIFC is home to an internationally recognised, independent regulator and a proven judicial system with an English common law framework, as well as the region’s largest financial ecosystem of 43,800 professionals working across over 6,150 active registered companies – making up the largest and most diverse pool of industry talent in the region. The Centre’s vision is to drive the future of finance through cutting-edge technology, innovation, and partnerships. Today, it is the global future of finance and innovation hub offering one of the region’s most comprehensive FinTech and venture capital environments, including cost-effective licensing solutions, fit-for-purpose regulation, innovative accelerator programmes, and funding for growth-stage start-ups. Comprising a variety of world-renowned retail and dining venues, a dynamic art and culture scene, residential apartments, hotels, and public spaces, DIFC continues to be one of Dubai’s most sought-after business and lifestyle destinations. For further information, please visit our website: difc.ae, or follow us on LinkedIn and X @DIFC.For media enquiries, please contact:Nivine William | Nisha CelinaBurson | bursonglobal.comnivine.william@bursonglobal.com | nisha.celina@bursonglobal.com Rasha Mezher | Dubai International Financial Centre Authority Manager, Marketing & Corporate CommunicationsRasha.Mezher@difc.ae Hussain AlZaabi | Dubai International Financial Centre AuthorityManager, DIFC Innovation Hubhussain.alzaabi@difc.ae Shadi DawiDirector - PR & Media+971 55 498 4989shadi@tresconglobal.com Copyright 2024 ACN Newswire via SeaPRwire.com.